DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer
Adding durvalumab to first-line chemotherapy delayed progression in advanced endometrial cancer, and adding the PARP inhibitor olaparib to durvalumab maintenance helped further in mismatch repair-proficient tumours.
Overview
Phase 3 trial of 718 patients with newly diagnosed advanced or recurrent endometrial cancer randomised to carboplatin-paclitaxel alone, with durvalumab followed by durvalumab maintenance, or with durvalumab followed by durvalumab plus olaparib maintenance.
Progression-free survival hazard ratios were 0.71 for durvalumab and 0.55 for durvalumab plus olaparib versus control; in mismatch repair-deficient disease both immunotherapy arms performed similarly (hazard ratio about 0.42), whereas olaparib added benefit in proficient disease (0.57 versus 0.77).
- Progression-free survival hazard ratio 0.71 (durvalumab) and 0.55 (durvalumab plus olaparib).
- Mismatch repair-proficient: hazard ratio 0.77 vs 0.57 with olaparib added.
Durvalumab-based chemo-immunotherapy is a third first-line option with RUBY and NRG-GY018, and durvalumab plus olaparib maintenance is approved for mismatch repair-proficient disease in some regions.
- The contribution of olaparib in proficient disease may be concentrated in p53-abnormal tumours; overall survival immature.
- Anaemia and neutropenia increased with olaparib.
Similar pages
not linked directly; found by shared links- PairingChemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer
Shares DUO-E / GOG-3041 / ENGOT-EN10, Advanced or recurrent endometrial cancer, Durvalumab, Carboplatin.
- TrialWoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
Shares Olaparib, Durvalumab.
- TrialA Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment
Shares Advanced or recurrent endometrial cancer, Durvalumab.
- TrialStudy of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
Shares Olaparib, Durvalumab, Carboplatin.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Olaparib, Durvalumab.
- Key paperCarboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma
Shares Journal of Clinical Oncology, Carboplatin.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Olaparib, Durvalumab.
- Key paperGOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma
Shares Journal of Clinical Oncology, Carboplatin.